GLSI-100’s Expanded Efficacy and Market Potential Drive Higher Valuation and Reiterated Buy Rating

In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Greenwich LifeSciences, with a price target of $50.00.

Yi Chen has given his Buy rating due to a combination of factors tied to both clinical strength and expanded commercial potential. Recent Phase 3 data from the FLAMINGO-01 trial indicate that GLSI-100 achieved about an 80% reduction in breast cancer recurrence in non-HLA-A*02 patients, closely mirroring the efficacy previously observed in HLA-A*02 patients and comparing favorably with currently approved therapies. Because non-HLA-A*02 patients make up a slightly larger share of the target population than HLA-A*02 patients, the new data imply that the addressable market for GLSI-100 could effectively double. Reflecting this, Chen raised the assumed probability of regulatory approval and increased projected peak sales, which in turn lifted his estimate of the company’s equity value and justified a higher price target of $50 per share.
In addition, Chen views the ongoing progress and planned expansion of the FLAMINGO-01 trial as a positive de-risking catalyst. The study is now supported by patient-driven demand, with strong enrollment across roughly 140 active sites and additional sites expected in North America and Europe. Oversight bodies, including the Data Safety Monitoring Board and the Steering Committee, have supported continuation and potential enlargement of the trial to boost statistical power, accelerate interim analyses, and refine study design if needed. Taken together, the robust and consistent efficacy signals, favorable safety trends, enlarged prospective market, and well-supported clinical development path underpin Chen’s decision to reiterate a Buy rating while raising the 12‑month price target.

In another report released on December 19, Noble Financial also reiterated a Buy rating on the stock with a $45.00 price target.